Evidence map›Paper›PMID 20502663›Full record

ArticlePloS one2010

Cell therapy of congenital corneal diseases with umbilical mesenchymal stem cells: lumican null mice.

Hongshan Liu, Jianhua Zhang, Chia-Yang Liu, I-Jong Wang, Martin Sieber, John Chang, James V Jester, Winston W Y Kao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 164 citations in OpenAlex.

  1. Trial
  2. Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026
    Review
  3. Article
  4. Review
  5. Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Corneal stromal regeneration-keratoconus cell therapy: a review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Review
  12. Cell-based Therapies for Corneal and Retinal Disorders.Stem cell reviews and reports · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hongshan LiuDepartment of Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States of America.
Jianhua Zhang
Chia-Yang Liu
I-Jong Wang
Martin Sieber
John Chang
James V Jester
Winston W Y Kao
University of Cincinnati · USNational Taiwan University · TWUniversity of California, Irvine Medical Center · US

Funding

Structure/Function Relationship of The Lumican GeneR01EY011845 · NEI · UNIVERSITY OF CINCINNATI · PI KAO, WINSTON W · 1999 to 2017
$5.2M
VISION RESEARCH INFRASTRUCTURE DEVELOPMENT GRANTR24EY016663 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI NESBURN, ANTHONY BART · 2005 to 2009
$1.1M
NEI NIH HHS EY 011845NEI NIH HHS EY016663NEI NIH HHS R01 EY011845NEI NIH HHS R24 EY016663
6 · The paper itself

Abstract

backgroundKeratoplasty is the most effective treatment for corneal blindness, but suboptimal medical conditions and lack of qualified medical personnel and donated cornea often prevent the performance of corneal transplantation in developing countries. Our study aims to develop alternative treatment regimens for congenital corneal diseases of genetic mutation. METHODOLOGY/PRINCIPAL

findingsHuman mesenchymal stem cells isolated from neonatal umbilical cords were transplanted to treat thin and cloudy corneas of lumican null mice. Transplantation of umbilical mesenchymal stem cells significantly improved corneal transparency and increased stromal thickness of lumican null mice, but human umbilical hematopoietic stem cells failed to do the same. Further studies revealed that collagen lamellae were re-organized in corneal stroma of lumican null mice after mesenchymal stem cell transplantation. Transplanted umbilical mesenchymal stem cells survived in the mouse corneal stroma for more than 3 months with little or no graft rejection. In addition, these cells assumed a keratocyte phenotype, e.g., dendritic morphology, quiescence, expression of keratocyte unique keratan sulfated keratocan and lumican, and CD34. Moreover, umbilical mesenchymal stem cell transplantation improved host keratocyte functions, which was verified by enhanced expression of keratocan and aldehyde dehydrogenase class 3A1 in lumican null mice. CONCLUSIONS/SIGNIFICANCE: Umbilical mesenchymal stem cell transplantation is a promising treatment for congenital corneal diseases involving keratocyte dysfunction. Unlike donated corneas, umbilical mesenchymal stem cells are easily isolated, expanded, stored, and can be quickly recovered from liquid nitrogen when a patient is in urgent need.

Indexed as

Mesenchymal Stem Cell TransplantationAldehyde DehydrogenaseAnimalsApoptosisBiomarkersCell ProliferationCell SeparationCell ShapeCell SurvivalChondroitin Sulfate ProteoglycansCollagenCorneaCorneal DiseasesDendritic CellsFlow CytometryHumansAldehyde DehydrogenaseAldh3a1 protein, mouseBiomarkersChondroitin Sulfate ProteoglycansCollagenKera protein, mouseKeratan SulfateLumicanLUM protein, humanLum protein, mouseProteoglycans

Identifiers

PMID20502663
PMCPMC2873411
OpenAlexW2128302033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.